Jeffrey Eisele - Jan 21, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Exec VP, Program Team Lead
Signature: /s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol: APLS
Transactions as of: Jan 21, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/25/2022, 03:50 PM
Previous filing: Dec 23, 2021
Next filing: Feb 1, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+26.1K	+353.38%	$0.00	33.4K	Jan 21, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+37K		$0.00	37K	Jan 21, 2022	Common Stock	37K	$35.46	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F2	This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.